Compare Moderna, Inc. (MRNA) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Open Text Corporation — how do they compare? Moderna, Inc. trades at $137.4 (market cap $56.02B), while Open Text Corporation trades at $22.6 (market cap $5.64B). The key difference: Moderna, Inc. is far larger — about 9.9× Open Text Corporation's market cap, and Open Text Corporation pays a 4.8% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | OTEX | |
|---|---|---|
Market Cap | $56.02B | $5.64B |
Sector | Health | Technology |
52-Week High | $174.38 | $39.69 |
52-Week Low | $22.36 | $20.01 |
Enterprise Value | $52.17B | $10.66B |
Dividend Yield | — | 4.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Open Text Corp (OTEX) trades at $23.36, down 2.46% on the day, with a bearish technical signal but attractive valuation multiples (P/E 9.05, P/S 1.11). Recent earnings beats (Q4 2025, Q1 2026, Q2 2026) and a 4.7% dividend yield highlight fundamental strength. The company announced a $105 million investment in European AI and cloud expansion (PRNewsWire, 2026-06-12), signaling growth initiatives amid mixed institutional positioning.
Outlook: Undervalued with strong cash flow and earnings momentum, but near-term technical pressure and high debt ($6.34B) pose risks. Analyst consensus target of $29.33 suggests 25% upside, supported by cloud revenue growth. Key risks include execution on AI investments and competitive software market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
